Ginkgo Bioworks Holdings (DNA) Gains from Investment Securities (2021 - 2024)
Ginkgo Bioworks Holdings (DNA) posted Gains from Investment Securities of -$1.5 million for Q3 2024, up 52.74% on a QoQ basis from -$3.2 million in Q2 2024, and up 19.2% year-over-year from -$1.3 million in Q4 2023.
Ginkgo Bioworks Holdings (DNA) Gains from Investment Securities (2021 - 2024) Analysis & Trends
Ginkgo Bioworks Holdings' Gains from Investment Securities history runs 4 years deep, the most recent figure standing at -$1.5 million for Q3 2024.
- Quarterly Gains from Investment Securities rose 19.2% year-over-year to -$1.5 million in Q3 2024, while the trailing twelve-month figure through Jun 2025 was -$1.5 million (up 87.89% YoY) and the FY2024 annual result came in at -$5.7 million, down 10.31% from the prior year.
- Gains from Investment Securities was -$1.5 million for Q3 2024 at Ginkgo Bioworks Holdings, up from -$3.2 million in the prior quarter.
- Across five years, Gains from Investment Securities topped out at $18.5 million in Q3 2021 and bottomed at -$85.0 million in Q1 2022.
- A 4-year average of -$15.0 million and a median of -$1.9 million in 2023 frame the typical range for Gains from Investment Securities.
- Annual changes were most pronounced in 2023 — Gains from Investment Securities jumped 119.07% — and 2024, when it tumbled 172.13%.
- Ginkgo Bioworks Holdings' Gains from Investment Securities stood at -$77.1 million in 2021, then jumped by 62.55% to -$28.9 million in 2022, then jumped by 77.3% to -$6.6 million in 2023, then jumped by 76.69% to -$1.5 million in 2024.
- Business Quant data shows DNA's Gains from Investment Securities at -$1.5 million in Q3 2024, -$3.2 million in Q2 2024, and -$940000.0 in Q1 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - |
| 10 | Ginkgo Bioworks Holdings | 445.24 Mn | 301.37 Mn | 16.38 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2024 | -1.53 Mn |
| Sep 30, 2024 | -1.53 Mn |
| Jun 30, 2024 | -3.23 Mn |
| Jun 30, 2024 | -3.23 Mn |
| Mar 31, 2024 | -940,000.00 |
| Mar 31, 2024 | -940,000.00 |
| Dec 31, 2023 | -6.56 Mn |
| Dec 31, 2023 | -6.56 Mn |
| Sep 30, 2023 | -1.89 Mn |
| Sep 30, 2023 | -1.89 Mn |
| Jun 30, 2023 | 4.48 Mn |
| Jun 30, 2023 | 4.48 Mn |
| Mar 31, 2023 | -1.20 Mn |
| Mar 31, 2023 | -1.20 Mn |
| Dec 31, 2022 | -28.87 Mn |
| Dec 31, 2022 | -28.87 Mn |
| Sep 30, 2022 | 12.45 Mn |
| Sep 30, 2022 | 12.45 Mn |
| Jun 30, 2022 | -23.51 Mn |
| Jun 30, 2022 | -23.51 Mn |